欧洲重症监护病房中年龄≥80岁呼吸衰竭患者以无创通气初始治疗在COVID-19大流行前后的结局比较
该研究合并两项前瞻性观察研究(VIP2 2018-2019年、COVIP 2020年3月至2023年1月),纳入欧洲ICU中因呼吸衰竭入院、以无创通气(NIV)为初始呼吸支持的≥80岁患者1986例(VIP2 1292例、COVIP 694例),中位年龄83岁,其中697例(35.1%)以NIV为主要呼吸支持方式。COVID-19相关ICU入院者较非COVID病因者30天死亡率更高(65.5% vs 36.5%,HR 2.18,95%CI 1.71-2.77)、插管更频繁(36.9% vs 17.5%,OR 2.63,95%CI 1.74-3.99)、NIV失败更多(76.2% vs 45.3%,OR 4.21,95%CI 2.84-6.34)。排除初级NIV期间引入生命支持治疗限制的患者后,敏感性分析仍显示COVID-19患者30天死亡率更高(52.5% vs 23.4%,HR 2.64,95%CI 1.83-3.80)。结论认为COVID-19大流行期间≥80岁接受NIV治疗的患者结局差于大流行前。
要点
- ≥80岁呼吸衰竭以NIV初始治疗者,COVID-19相关ICU入院30天死亡率65.5%,非COVID病因36.5%(HR 2.18,95%CI 1.71-2.77)。
- COVID-19组插管率36.9%,非COVID组17.5%(OR 2.63,95%CI 1.74-3.99)。
- COVID-19组NIV失败(30天内死亡或插管)率76.2%,非COVID组45.3%(OR 4.21,95%CI 2.84-6.34)。
- 排除初级NIV期间引入生命支持治疗限制者后,COVID-19组30天死亡率仍更高(52.5% vs 23.4%,HR 2.64,95%CI 1.83-3.80)。
- 最终队列1986例(VIP2 1292例、COVIP 694例),中位年龄83岁,697例(35.1%)以NIV为主要呼吸支持方式。
适用人群与场景
- 欧洲ICU中因呼吸衰竭入院的≥80岁危重患者,数据来自VIP2(2018-2019年,大流行前)与COVIP(2020年3月至2023年1月,COVID-19)两项前瞻性观察研究的合并队列。
- 最终队列1986例(VIP2 1292例、COVIP 694例),中位年龄83岁;其中697例(35.1%)以NIV作为主要呼吸支持方式。
研究设计与关键结果
- 研究类型:两项前瞻性观察研究(VIP2 2018-2019年、COVIP 2020年3月至2023年1月)的合并队列分析;最终队列1986例(VIP2 1292例、COVIP 694例),中位年龄83岁。
- NIV作为主要呼吸支持方式者697例(35.1%);主要结局为30天死亡率、插管率和NIV失败(30天内死亡或插管)。
- COVID-19相关ICU入院 vs 非COVID病因:30天死亡率65.5% vs 36.5%(HR 2.18,95%CI 1.71-2.77)。
- COVID-19相关ICU入院 vs 非COVID病因:插管率36.9% vs 17.5%(OR 2.63,95%CI 1.74-3.99)。
- COVID-19相关ICU入院 vs 非COVID病因:NIV失败率76.2% vs 45.3%(OR 4.21,95%CI 2.84-6.34)。
- 敏感性分析排除初级NIV期间引入生命支持治疗限制的患者后,COVID-19患者30天死亡率仍更高(52.5% vs 23.4%,HR 2.64,95%CI 1.83-3.80)。
证据类型、等级与局限
- 证据类型:两项前瞻性观察研究的合并队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于≥80岁因呼吸衰竭入ICU并以NIV初始治疗的患者,COVID-19相关病因者30天死亡率、插管率和NIV失败率均高于非COVID病因者,提示临床团队应更早评估NIV反应并准备升级呼吸支持。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Non-invasive ventilation (NIV) has been commonly used to treat acute respiratory failure due to COVID-19. In this study we aimed to compare outcomes of older critically ill patients treated with NIV before and during the COVID-19 pandemic.
METHODS: We analysed a merged cohort of older adults admitted to intensive care units (ICUs) due to respiratory failure. Patients were enrolled into one of two prospective observational studies: before COVID-19 (VIP2-2018 to 2019) and admitted due to COVID-19 (COVIP-March 2020 to January 2023). The outcomes included: 30-day mortality, intubation rate and NIV failure (death or intubation within 30 days).
RESULTS: The final cohort included 1986 patients (1292 from VIP2, 694 from COVIP) with a median age of 83 years. NIV was used as a primary mode of respiratory support in 697 participants (35.1%). ICU admission due to COVID-19 was associated with an increased 30-day mortality (65.5% vs. 36.5%, HR 2.18, 95% CI 1.71 to 2.77), more frequent intubation (36.9% vs. 17.5%, OR 2.63, 95% CI 1.74 to 3.99) and NIV failure (76.2% vs. 45.3%, OR 4.21, 95% CI 2.84 to 6.34) compared to non-COVID causes of respiratory failure. Sensitivity analysis after exclusion of patients in whom life supporting treatment limitation was introduced during primary NIV confirmed higher 30-day mortality in patients with COVID-19 (52.5% vs. 23.4%, HR 2.64, 95% CI 1.83 to 3.80).
CONCLUSION: The outcomes of patients aged ≥80 years treated with NIV during COVID-19 pandemic were worse compared then those treated with NIV in the pre-pandemic era.
参考来源
- Polok K, Fronczek J, Guidet B, et al. Outcomes of patients aged ≥80 years with respiratory failure initially treated with non-invasive ventilation in European intensive care units before and during COVID-19 pandemic. Ann Intensive Care. 2023. PMID: 37698708. doi:10.1186/s13613-023-01173-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。